XML 34 R23.htm IDEA: XBRL DOCUMENT

Subsequent Event	9 Months Ended
Subsequent Event	Sep. 30, 2016
Subsequent event
Subsequent event	16. Subsequent Event In October 2016, we were notified of a $40.0 million regulatory milestone from Novartis related to reimbursement of JAKAVI in Europe for the treatment of patients with polycythemia vera. We expect to record this amount as contract revenue in the three months ending December 31, 2016.